Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 6/20 | 0.40 |
| ▸ | FNTB | P49356 | 6/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.40 |
| ▸ | NPY4R | P50391 | 10/20 | 0.38 |
| ▸ | NPY1R | P25929 | 6/20 | 0.38 |
| ▸ | NPY2R | P49146 | 4/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29449792 | 1.00 | PTGS1 (0.41) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL29568701 | 0.94 | PTGS1 (0.43) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL30509912 | 0.94 | PTGS1 (0.43) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL30767724 | 0.94 | PTGS1 (0.43) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL30509913 | 0.94 | PTGS1 (0.43) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL4755266 | 0.92 | PTGS1 (0.46) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL23391080 | 0.91 | PTGS1 (0.41) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL23391083 | 0.91 | PTGS1 (0.41) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL23391087 | 0.91 | PTGS1 (0.41) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL31236827 | 0.90 | IL23R (0.42) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240358710-A1 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES | AF CHEMICALS, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-12023339-B2 | Methods, compositions and devices for treating cancer with illudofulvenes | AF CHEMICALS, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-20220040191-A1 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES | AF CHEMICALS, LLC (US) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040191-A1 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES | MYC, MYCBP, TP53 | PTGS1 2773/4885GSTK1 2542/4885FNTA 2046/4885 |
| US-20240358710-A1 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES | MYC, MYCBP, TP53 | PTGS1 2773/4885GSTK1 2542/4885FNTA 2046/4885 |
| US-12023339-B2 | Methods, compositions and devices for treating cancer with illudofulvenes | MYC, MYCBP, TP53 | PTGS1 2773/4885GSTK1 2542/4885FNTA 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.